Oral immunization with recombinant hepatitis E virus antigen displayed on the Lactococcus lactis surface enhances ORF2-specific mucosal and systemic immune responses in mice

International Immunopharmacology

Volumn 24, Issue 1, 2015, Pages 140-145

  Gao, Shenyang ^a,c   Li, Dandan ^b   Liu, Ying ^a   Zha, Enhui ^a   Zhou, Tiezhong ^a   Yue, Xiqing ^a,c  

^a JINZHOU MEDICAL UNIVERSITY   (China)

^b Department of Food Science and Engineering Liaoning Medical University ^*  (China)

^c SHENYANG AGRICULTURAL UNIVERSITY   (China)

Author keywords

Hepatitis E virus; Ice nucleation protein; Lactococcus lactis; Oral immunization

Indexed keywords

BACTERIAL VACCINE; HEPATITIS E ANTIGEN; HEPATITIS E VACCINE; HYBRID PROTEIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 4; RECOMBINANT ANTIGEN; HEPATITIS VACCINE; ICE NUCLEATION PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; ORF2 PROTEIN, HEPATITIS E VIRUS; OUTER MEMBRANE PROTEIN; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL STRAIN; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; FUSION GENE; GENE FUSION; HEPATITIS E; HEPATITIS E VIRUS; IMMUNE RESPONSE; IMMUNIZATION; LACTOCOCCUS LACTIS; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; RECOMBINANT PLASMID; SPLEEN CELL; T LYMPHOCYTE; UROGENITAL SYSTEM; VIRUS CAPSID; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BLOOD; GENETICS; HUMAN; IMMUNOLOGY; MUCOSAL IMMUNITY; ORAL DRUG ADMINISTRATION; ZOONOSES;

ADMINISTRATION, ORAL; ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; FEMALE; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LACTOCOCCUS LACTIS; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; VIRAL HEPATITIS VACCINES; VIRAL PROTEINS; ZOONOSES;

EID: 84919880276     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2014.10.032     Document Type: Article

References (27)

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-128.
2. Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J, et al. Hepatitis E. Lancet 2012;379:2477-88.
3. Schlauder GG, Dawson GJ, Erker JC, Kwo PY, Knigge MF, Smalley DL, et al. The sequence and phylogenetic analysis of a novel hepatitis E virus isolated from a patient with acute hepatitis reported in the United States. J Gen Virol 1998;79(Pt 3):447-56.
4. Meng XJAD, Arankalle VA, Emerson SU, Harrison TJ, Jameel S, Hepeviridae Okamoto H, et al, editors. Virus Taxonomy Ninth Report of the ICTV. London: Elsevier/Academic Press; 2012. p. 1021-8.
5. Aggarwal R, Jameel S. Hepatitis E vaccine. Hepatol Int 2008;2:308-15.
6. Shrestha MP, Scott RM, Joshi DM, Mammen Jr MP, Thapa GB, Thapa N, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 2007;356:895-903.
7. Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010;376:895-902.
8. Zhao Q, Zhang J, Wu T, Li SW, Ng MH, Xia NS, et al. Antigenic determinants of hepatitis E virus and vaccine-induced immunogenicity and effi cacy. J Gastroenterol 2013;48:159-68.
9. de Ruyter PG, Kuipers OP, Beerthuyzen MM, van Alen-Boerrigter I, de Vos WM. Functional analysis of promoters in the nisin gene cluster of Lactococcus lactis. J Bacteriol 1996;178:3434-9.
10. Mierau I, Kleerebezem M. 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. Appl Microbiol Biotechnol 2005;68:705-17.
11. Wells JM, Wilson PW, Le Page RW. Improved cloning vectors and transformation procedure for Lactococcus lactis. J Appl Bacteriol 1993;74:629-36.
12. Shenyang G, Dandan L, Chen F, Shuliang W, Tiezhong Z. Design and evaluation of a recombinant multi-epitope-based ELISA for the serological surveillance of HEV infection in northern China. Arch Virol 2011;156:1621-6.
13. Cortes-Perez NG, Bermudez-Humaran LG, Le Loir Y, Rodriguez-Padilla C, Gruss A, Saucedo-Cardenas O, et al. Mice immunization with live lactococci displaying a surface anchored HPV-16 E7 oncoprotein. FEMS Microbiol Lett 2003;229:37-42.
14. Wang Z, Yu Q, Gao J, Yang Q. Mucosal and systemic immune responses induced by recombinant Lactobacillus spp. expressing the hemagglutinin of the avian influenza virus H5N1. Clin Vaccine Immunol 2012;19:174-9.
15. Wang Z, Gao J, Yu Q, Yang Q. Oral immunization with recombinant Lactococcus lactis expressing the hemagglutinin of the avian influenza virus induces mucosal and systemic immune responses. Future Microbiol 2012;7:1003-10.
16. Ishiyama M, Miyazono Y, Sasamoto K, Ohkura Y, Ueno K. A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability. Talanta 1997;44:1299-305.
17. Schofield DJ, Glamann J, Emerson SU, Purcell RH. Identification by phage display and characterization of two neutralizing chimpanzee monoclonal antibodies to the hepatitis E virus capsid protein. J Virol 2000;74:5548-55.
18. Meng J, Dai X, Chang JC, Lopareva E, Pillot J, Fields HA, et al. Identification and characterization of the neutralization epitope(s) of the hepatitis E virus. Virology 2001;288:203-11.
19. Zhou YH, Purcell RH, Emerson SU. An ELISA for putative neutralizing antibodies to hepatitis E virus detects antibodies to genotypes 1, 2, 3, and 4. Vaccine 2004;22:2578-85.
20. Kalia M, Chandra V, Rahman SA, Sehgal D, Jameel S. Heparan sulfate proteoglycans are required for cellular binding of the hepatitis E virus ORF2 capsid protein and for viral infection. J Virol 2009;83:12714-24.
21. Yamada K, Takahashi M, Hoshino Y, Takahashi H, Ichiyama K, Tanaka T, et al. Construction of an infectious cDNA clone of hepatitis E virus strain JE03-1760F that can propagate efficiently in cultured cells. J Gen Virol 2009;90:457-62.
22. Ferreira DM, Darrieux M, Silva DA, Leite LC, Ferreira Jr JM, Ho PL, et al. Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice. Clin Vaccine Immunol 2009;16:636-45.
23. Zhang Q, Hou H, Lu Y, Chen W, Zhong J. Construction of cell surface display systemin lactic acid bacteria by using ice nucleation protein. Wei Sheng Wu Xue Bao 2013;53:397-402.
24. Jung HC, Park JH, Park SH, Lebeault JM, Pan JG. Expression of carboxymethylcellulase on the surface of Escherichia coli using Pseudomonas syringae ice nucleation protein. Enzyme Microb Technol 1998;22:348-54.
25. Li Q, Yan Q, Chen J, He Y, Wang J, Zhang H, et al. Molecular characterization of an ice nucleation protein variant (inaQ) from Pseudomonas syringae and the analysis of its transmembrane transport activity in Escherichia coli. Int J Biol Sci 2012;8:1097-108.
26. Wells JM, Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 2008;6:349-62.
27. Woof JM, Mestecky J. Mucosal immunoglobulins. Immunol Rev 2005;206:64-82.